| Bioactivity | AcBut-N-Ac-γ-Calicheamicin is an ADC cytotoxic payload that induces cell cycle arrest and apoptosis by causing DNA double-strand breaks. AcBut-N-Ac-γ-Calicheamicin is primarily used in the synthesis of antibody-drug conjugates (ADC) and holds promise for research in the field of cancer, including acute lymphoblastic leukemia (ALL) and other hematological malignancies[1]. |
| CAS | 174885-02-0 |
| Formula | C77H99IN6O28S3 |
| Molar Mass | 1779.73 |
| Appearance | 固体 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Lamb Y N. Inotuzumab ozogamicin: first global approval[J]. Drugs, 2017, 77: 1603-1610. |
N-Ac-γ-Calicheamicin-AcBut-NHS ester
CAS: 174885-02-0 F: C77H99IN6O28S3 W: 1779.73
AcBut-N-Ac-γ-Calicheamicin is an ADC cytotoxic payload that induces cell cycle arrest and apoptosis by causing DNA doub
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.